Favorable Pharmacokinetic and Pharmacodynamic Properties of Gilteritinib in Cerebrospinal Fluid: a Potential Effective Treatment in Relapsing Meningeal Acute Myeloid Leukemia -ITD Patients

Overview

Journal Haematologica

Specialty Hematology

Date 2023 Feb 16

PMID 36794507

Authors

Nicolas Vignal

Lois Kelly

Etienne Lengline

Aurelie Cabannes-Hamy

Justine Siavellis

David Ghez

Helene Sauvageon

Thorsten Braun

Evelyne Jacqz-Aigrain

Milena Kohn

Philippe Rousselot

Alexandre Puissant

Emmanuel Raffoux

Samia Mourah

Lauriane Goldwirt

Affiliations

Soon will be listed here.

Citing Articles

Central nervous system relapse after allogeneic HCT in FLT3-mutated AML.

Kouidri K, Acker F, Toenges R, Pfaff S, Lindner S, Riemann J Ann Hematol. 2024; 103(12):5387-5393.

PMID: 39589497 PMC: 11695448. DOI: 10.1007/s00277-024-06106-y.

Gilteritinib: The Story of a Proceeding Success into Hard-to-Treat -Mutated AML Patients.

Molica M, Perrone S, Rossi M J Clin Med. 2023; 12(11).

PMID: 37297842 PMC: 10253262. DOI: 10.3390/jcm12113647.

References

Ganzel C, Lee J, Fernandez H, Paietta E, Luger S, Lazarus H . CNS involvement in AML at diagnosis is rare and does not affect response or survival: data from 11 ECOG-ACRIN trials. Blood Adv. 2021; 5(22):4560-4568. PMC: 8759130. DOI: 10.1182/bloodadvances.2021004999. View

Milne P, Wilhelm-Benartzi C, Grunwald M, Bigley V, Dillon R, Freeman S . Serum Flt3 ligand is a biomarker of progenitor cell mass and prognosis in acute myeloid leukemia. Blood Adv. 2019; 3(20):3052-3061. PMC: 6849950. DOI: 10.1182/bloodadvances.2019000197. View

Daver N, Perl A, Maly J, Levis M, Ritchie E, Litzow M . Venetoclax Plus Gilteritinib for -Mutated Relapsed/Refractory Acute Myeloid Leukemia. J Clin Oncol. 2022; 40(35):4048-4059. PMC: 9746764. DOI: 10.1200/JCO.22.00602. View

Chiney M, Menon R, Bueno O, Tong B, Salem A . Clinical evaluation of P-glycoprotein inhibition by venetoclax: a drug interaction study with digoxin. Xenobiotica. 2017; 48(9):904-910. DOI: 10.1080/00498254.2017.1381779. View

Perl A, Martinelli G, Cortes J, Neubauer A, Berman E, Paolini S . Gilteritinib or Chemotherapy for Relapsed or Refractory -Mutated AML. N Engl J Med. 2019; 381(18):1728-1740. DOI: 10.1056/NEJMoa1902688. View

James A, Smith C, Litzow M, Perl A, Altman J, Shepard D . Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor. Clin Pharmacokinet. 2020; 59(10):1273-1290. PMC: 7550323. DOI: 10.1007/s40262-020-00888-w. View

Siegal T, Benouaich-Amiel A, Bairey O . Neurologic complications of acute myeloid leukemia. Diagnostic approach and therapeutic modalities. Blood Rev. 2021; 53:100910. DOI: 10.1016/j.blre.2021.100910. View

Mori M, Kaneko N, Ueno Y, Yamada M, Tanaka R, Saito R . Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia. Invest New Drugs. 2017; 35(5):556-565. PMC: 5613053. DOI: 10.1007/s10637-017-0470-z. View

Bennett J, Catovsky D, Daniel M, Flandrin G, GALTON D, Gralnick H . Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol. 1976; 33(4):451-8. DOI: 10.1111/j.1365-2141.1976.tb03563.x. View

10.

Perl A, Altman J, Cortes J, Smith C, Litzow M, Baer M . Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study. Lancet Oncol. 2017; 18(8):1061-1075. PMC: 5572576. DOI: 10.1016/S1470-2045(17)30416-3. View

11.

Perrone S, Ortu La Barbera E, Viola F, Cipollone E, Scerpa M, Siniscalchi R . A Relapsing Meningeal Acute Myeloid Leukaemia FLT3-ITD+ Responding to Gilteritinib. Chemotherapy. 2021; 66(4):134-138. DOI: 10.1159/000518356. View

12.

Del Principe M, Buccisano F, Soddu S, Maurillo L, Cefalo M, Piciocchi A . Involvement of central nervous system in adult patients with acute myeloid leukemia: Incidence and impact on outcome. Semin Hematol. 2018; 55(4):209-214. DOI: 10.1053/j.seminhematol.2018.02.006. View

13.

. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-2405. Blood. 2019; 128(3):462-463. DOI: 10.1182/blood-2016-06-721662. View